

Liu
2011
FibroTest**FibroTest is cost effective**

Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients. *PLoS One.* 2011;6:e26783
Stanford University USA, has evaluated the cost-effectiveness of FibroTest and liver biopsy used in six strategies for the treatment of patients with chronic hepatitis C: FibroTest alone, FibroTest associated with liver biopsy for ambiguous results, FibroTest followed by a biopsy to rule out / confirm significant fibrosis, biopsy alone. As a conclusion authors stated that in clinical practice where the test is required before treatment, FibroTest alone is more effective and less costly than liver biopsy.

Poynard
2012
Elasto-FibroTest**Elasto-FibroTest®**

Performances of Elasto-FibroTest®, a combination between FibroTest® and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C. *Clin Res Hepatol Gastroenterol.* 2012 (Sep 5).
The diagnostic performance of the FibroTest and liver stiffness measurement (LSM) combination was evaluated among 1289 patients with chronic hepatitis C with concomitant biopsy and 604 healthy volunteers. For the diagnosis of cirrhosis, Elasto-FibroTest® has superior performance to FibroTest or FibroScan alone, however, for the diagnosis of advanced fibrosis there was no improvement in performance compared to FibroTest alone.

Poynard
2012
FibroTestJ Hepatol
Editor's Pick**Fibrosis progression: 342,346 FibroTests**

Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population. *J Hepatol.* 2012;57:541-8.

September 2012, the Journal of Hepatology Editor pick: 342,346 FibroTests in the world to study the factors of fibrosis progression to cirrhosis. The fastest growth is associated with alcoholic liver disease in men - a 10-year advanced risk compared to women - the slower for women with non-alcoholic fatty liver disease. Other factors associated with progression to cirrhosis are co-infection with HIV-HCV and residency in the Middle East or Eastern Europe.

DeLedinghen
2012
FibroTest**Diabetics screened with FibroTest**

Screening for liver fibrosis by using FibroScan and FibroTest in patients with diabetes. *Dig Liver Dis.* 2012;44:413-8.

The Bordeaux team has made a non-invasive detection of severe liver fibrosis using FibroTest and liver stiffness measurement (LSM) in 277 diabetic patients hospitalized. This study showed a high prevalence of severe fibrosis in patients hospitalized with diabetes, especially in patients aged 50 years or older with type 2 diabetes or with a history of diabetic foot.

Kim
2012
FibroTest HBV**New HBV Asian validation - Prognostic**

Prospective Validation of ELF Test in Comparison with Fibroscan and FibroTest to Predict Liver Fibrosis in Asian Subjects with Chronic Hepatitis B. *PLoS One.* 2012;7:e41964.

170 patients were included with HBV biopsy, FibroTest, ELF and measurement of liver stiffness (LSM) by Fibroscan. The diagnostic values (AUROC) for predicting $F \geq 2$ were similar between tests, while FibroTest AUROC and MEF are better than ELF to predict $F \geq 3$ ($p < 0.05$). These results further confirm those recently published in meta-analyses of FibroTest in HBV (Poynard et al. *Curr Hepatitis Rep* 2011)

Chládek
2012
FibroTest**Methotrexate (MTX) and FibroTest**

Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers. *J Eur Acad Dermatol Venereol.* 2012 Aug 7.

The authors aimed to compare the results of measurements of serum markers of fibrosis in the initial phase of remission of psoriasis with MTX than patients treated long-term MTX (> 2 years). The authors concluded that markers of fibrosis such as hyaluronic acid and algorithms that include as Hepascore less liver-specific and more likely to reflect the activity of psoriasis compared to FibroTest.

FibroTest/FibroMax Scientific Publications

Key publications for 2012

2012 FibroTest Steatosis

FibroTest in children with steatosis

Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study. *Ann Hepatol.* 2012;11:364-8.

68 children of mean age 10 years (1-17 years) with chronic liver diseases, mainly steatosis, autoimmune hepatitis, biliary atresia and metabolic diseases were included with FibroTest, APRI and biopsy. The diagnostic value (AUROC) of FibroTest for advanced fibrosis (F3F4) was 0.90. Based on these results the authors propose the FibroTest to select patients for biopsy, fibrosis screening before clinical and biological signs and follow patients longitudinally.

Poynard 2012 FibroTest

Liver biopsy grey zone


Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis. *Clin Gastroenterol Hepatol.* 2012;10:657-63.e7

We examined whether the performance of non-invasive tests such as FibroTest for the diagnosis of intermediate stages of fibrosis (F2vsF1) results from the biopsy limits even for F2vsF1. We analyzed 27,869 digitized images of virtual biopsies of different sizes (5 to 30mm) from surgical explants. The performance of the biopsy was worse for diagnosing F2 vs. F1 than for F1vsF0 or F4vsF3, even for samples of 30-mm. Contrary to what is often said, the recommendation to perform biopsy instead of a noninvasive marker for the diagnosis of intermediate stages of fibrosis is not scientifically validated.

Our solutions

FibroTest

FibroTest pack contains FibroTest and Actitest



Assays


- ▶ Alpha-2 macroglobulin
- ▶ Haptoglobin
- ▶ Apolipoprotein A I
- ▶ Total Bilirubin
- ▶ GGT
- ▶ ALT

+ age + sex

+ computation on biopredictive.com

FibroMax

FibroMax pack contains all tests
(FibroTest, SteatoTest, ActiTest, NashTest et AshTest)



Assays

- ▶ Alpha-2 macroglobulin
- ▶ Haptoglobin
- ▶ Apolipoprotein A I
- ▶ Total Bilirubin
- ▶ GGT
- ▶ ALT + AST
- ▶ Total Cholesterol
- ▶ Triglycerides
- ▶ Fasting Glucose

+ age + sex + height + weight

+ computation on biopredictive.com

Find all the scientific publications of BioPredictive non-invasive tests on the website :

www.biopredictive.com

BioPredictive S.A.
40 rue du Bac
75007 PARIS
Tel : +33 1 45 44 30 64

